

Reducing Hyperglycemia without Over-Stimulation of β -cells: Prevention Rather than Cure Type 2 Diabetes

Lorea Zubiaga*^{1,2}

¹Inserm Umr1190, Translational Research Laboratory for Diabetes, Lille, France

²European Genomic Institute for Diabetes, Lille, France

Corresponding Author*

Lorea Zubiaga

Inserm Umr1190, Translational Research Laboratory for Diabetes, Lille, France

Tel: +33603292899

Email: loreazubiaga@gmail.com

Copyright: © 2022 Lorea Zubiaga. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Received: 05-Jan-2022, Manuscript No. jdm-22-15740; **Editor assigned:** 07-Jan-2022, PreQC No. jdm-22-15740(PQ); **Reviewed:** 21-Jan-2022, QC No. jdm-22-15740; **Revised:** 24-Jan-2022, Manuscript No. jdm-22-15740(R); **Published:** 31-Jan-2022, DOI: 10.35248/2155-6156.1000917

Alimentary overload has been described as a key factor that induces persistent hyperglycemia. Similarly, circulating glucose is the main factor that induces insulin secretion. In the presence of sustained hyperglycemia, the pancreas is forced into a state of compensatory hyperinsulinemia to control glucose levels in the blood [1]. The hyperinsulinism is maintained until a point at which further over-secretion is no longer possible due to impair of β -cell function. Thus, hyperinsulinism has been proposed as an independent predictive factor for the development of Type 2 Diabetes Mellitus (T2D).

However, the molecular mechanisms underlying the progressive decline in β -cell mass and functions remain controversial. β -cells adjust their mass according to demand and rises in β -cells number have been observed only during situations of increased metabolic demand, such as pregnancy or obesity. In conditions of induced β -cell stress, these cells undergo a dedifferentiation process, losing the expression of crucial signature genes such as Nkx6.1, which is a key driver of insulin biosynthesis and glucose metabolism in mature cells. Metabolic surgery achieves a consistent long-term control of glycemia in T2D.

However, the mechanisms of action mediating the remission of diabetes after surgery remain still elusive. Therefore, there are doubts that whether metabolic surgery improves only hyperglycemia in T2D or whether it modifies the disease's progression. For this reason, we hypothesized that surgery is able reducing glucotoxicity (by intestinal mechanisms) without over-stimulation of β -cells. For this purpose, we used a Goto-Kakizaki (GK) rat model that spontaneously develops T2D during life due to a progressive loss in β -cell [2]. We choose a duodenal jejunal exclusion bypass (DJB) as surgical technique and we performed the surgery at different weeks of life (12, 16 and 20 weeks of age), which correspond to early, intermediate and late stages of T2D progression. Sham operated GK rats served as controls. We found that DJB in GK rats resulted in a marked reduction in postprandial glucose excursion and decreased plasma insulin levels compared to the sham operated rats in all stages [3].

These results show that surgery corrects glycemia in all stages of the disease. However, we found that fibrosis infiltration was only prevented in animals that

underwent an early DJB. If the surgeries were performed in late stages, the fibrosis did not disappear. Of note, surgery did not promote an increase of β -cell mass, but preserved Nkx6.1 expression (a marker of mature functional β -cells), thus indicating that early surgical intervention prevented the progression of T2D [4].

Despite the good results of surgery in glycemic control, our results suggest that surgery prevents rather than reverses pancreatic damage; therefore, early treatments are preferable to avoid T2D progression [5]. These results propose an explanation for the poor results in patients with advanced disease and T2D relapses over the years after metabolic surgery.

Biography

Lorea Zubiaga (MD -2006- PhD -2015- "Miguel Hernández" University, Spain) is a digestive surgeon trained in SECO-Spanish system (Spanish Society for obesity and metabolic diseases) who developed her scientific thesis on metabolic surgery for Type 2 Diabetes (T2D). She began her postdoc in Lille, on May 2017 in the European Genomic Institute for Diabetes in U-1190. The aim of her postdoc project is to unveil new hypothesizes on T2D treatment associated to the intestinal mechanism of absorption, specifically related with gluco-transporters activity in the gut. To address this idea, she is performing 3 specific projects:

1. To assess the importance of the gut reprogramming after surgery to prevent the pancreatic damage in T2D
2. To demonstrate the physiological and pathophysiological relevance of the gluco-transporters in different animal models regarding the effect of bariatric surgery
3. To demonstrate the physiological and pathophysiological relevance of these findings to evaluate pharmacological molecules which could be able to imitate the surgery effects?. She has several publications in scientific journals and she has been a speaker in different national and international events.

References

1. Erion K, Corkey BE (2018) Beta-Cell Failure or beta-Cell Abuse?. *Front Endocrinol* 9:532.
2. DiNicolantonio JJ, Bhutani J, OKeefe JH, Crofts C (2017) Postprandial insulin assay as the earliest biomarker for diagnosing pre-diabetes, T2D and increased cardiovascular risk. *Open heart* 4: e000656.
3. Kelly CT (2014) Hyperinsulinemic syndrome: the metabolic syndrome is broader than you think. *Surgery* 156:405-411.
4. Pories WJ, Dohm GL (2012) Diabetes: have we got it all wrong? Hyperinsulinism as the culprit: surgery provides the evidence. *Diab care* 35: 2438-2442.
5. Schauer PR, Bhatt DL, Kashyap SR (2017) Bariatric Surgery or Intensive Medical Therapy for Diabetes after five Years. *N Engl J Med* 376(7):641-651.